CSIMarket
 
Accolade Inc   (NASDAQ: ACCD)
    Sector  Services    Industry Professional Services
   Industry Professional Services
   Sector  Services
 
Price: $7.0200 $-0.01 -0.142%
Day's High: $7.03 Week Perf: 0.43 %
Day's Low: $ 7.01 30 Day Perf: 0.72 %
Volume (M): 4,585,600 52 Wk High: $ 0.00
Volume (M$): $ 32,191 52 Wk Avg: $0.00
Open: $7.03 52 Wk Low: $0.00



 Market Capitalization (Millions $) 566
 Shares Outstanding (Millions) 81
 Employees 2,400
 Revenues (TTM) (Millions $) 447
 Net Income (TTM) (Millions $) -180
 Cash Flow (TTM) (Millions $) -44
 Capital Exp. (TTM) (Millions $) 6

Business Description


Accolade Inc is a US-based healthcare technology company that provides personalized healthcare assistance to individuals and employees of various corporations. Founded in 2007, Accolade has established itself as a leader in providing technology-enabled healthcare solutions that improve patient outcomes and reduce healthcare costs.

The company's main objective is to provide personalized, proactive support and advocacy to its clients, which helps them navigate the complexities of the healthcare system in order to obtain optimal outcomes. To achieve this, Accolade has developed a platform that integrates various healthcare data sources to provide a complete view of each patient's healthcare history.

The company's services are primarily targeted at two groups: individuals and employees. For individuals, Accolade provides support to help them find the right doctors, schedule appointments, and manage chronic conditions. For employees, Accolade partners with corporations to provide personalized healthcare support to their employees, which helps the employees manage their health and wellness, leading to reduced absenteeism, increased productivity, and lower healthcare costs.

Accolade's solution is designed to be scalable, flexible, and easy to integrate with existing healthcare systems. It uses advanced analytics and machine learning algorithms to identify individuals who are at risk of developing chronic conditions or requiring hospitalization. By intervening early, Accolade can help prevent these conditions from worsening, which leads to lower healthcare costs for patients and employers.

In addition to its core services, Accolade also offers a range of custom solutions for employers, including integration with existing wellness and employee assistance programs, as well as customized communications and marketing materials to promote healthcare education and awareness.

Accolade has received numerous awards and recognitions for its innovative approach to healthcare, including being named one of the "World's Most Innovative Companies" by Fast Company and the "Top AI-Powered Healthcare Company" by Forbes. The company has also raised over $500 million in funding from investors, including Andreessen Horowitz and GV (Google Ventures).

Overall, Accolade is a leading healthcare technology company that is helping individuals and corporations navigate the complexities of the healthcare system to achieve better patient outcomes and lower healthcare costs. Its innovative platform and personalized, proactive approach make it an ideal partner for healthcare providers and employers looking to improve their healthcare offerings.


   Company Address: 1201 Third Avenue Seattle 98101 WA
   Company Phone Number: 926-8100   Stock Exchange / Ticker: NASDAQ ACCD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMWL        8.89% 
HQY   -0.31%    
GDRX   -1.42%    
TDOC   -3.38%    
• View Complete Report
   



Merger and Acquisition

Accolades Big Move: Stockholders Approve Merger with Transcarent Amidst Stock Price Challenges

Published Thu, Mar 27 2025 8:05 PM UTC

In a significant shakeup within the healthcare technology sector, Accolade Inc. (NASDAQ: ACCD) has received the green light for its merger with Transcarent. The decision was made during a special meeting of stockholders held on March 27, 2025, where the majority voted in favor of the merger, reflecting a pivotal moment for the company. As Accolade prepares to take the next s...

Merger and Acquisition

Transcarent and Accolade’s Merger Moves Forward as Antitrust Waiting Period Expires

Published Mon, Feb 24 2025 10:21 PM UTC

SAN FRANCISCO and SEATTLE, Feb. 24, 2025 – In a significant development for the healthcare industry, Transcarent, known as the One Place for Health and Care, has announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 has officially expired regarding its merger with Accolade (NASDAQ: ACCD). This paves the way for the strategic...

Merger and Acquisition

Transcarents Strategic Acquisition of Accolade: A Game-Changer in Consumer-Centric Healthcare Solutions

Published Wed, Jan 8 2025 1:30 PM UTC

In a significant move poised to reshape the healthcare technology landscape, Transcarent has announced its acquisition of Accolade Inc. a pioneering company known for its personalized advocacy in healthcare. This merger seeks to consolidate resources and enhance their shared objective of consumer empowerment in an increasingly complex healthcare environment. Together, the ne...

Stocks on the Move

Accolade Inc Faces Challenges amidst Strike, Investigations, and Acquisitions

Published Mon, Jul 22 2024 7:16 PM UTC

Throughout the month, Accolade Inc has experienced a decline in the performance of its shares compared to the overall market. This article will cover various news events that have contributed to the company s recent struggles, including a strike in Ontario, investigations into potential securities fraud, new talent emerging in the music industry, environmental recognition, a...

Stocks on the Move

Accolade Inc Behind the Market Performance Lag and Unrelated Accolades

Published Fri, Jul 12 2024 5:07 PM UTC

Accolade Inc Lagging behind the Market Performance: A Closer Look at Recent DevelopmentsThroughout this month, Accolade Inc shares have been underperforming, trailing the overall market performance. Year to date, Accolade Inc shares have also fallen behind, showing a decline of 18.79% compared to the market s performance. In order to understand the reasons behind this trend,...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.27
Price to Sales (Expected) -
Price to Book 1.81
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.79
Working Capital Ratio 2.63
Leverage Ratio (MRQ) 1.07
Total Debt to Equity 0.67
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.25 $
Revenues (TTM) 5.54 $
Cash Flow (TTM) -
Cash 2.31 $
Book Value 3.88 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 186,133
Net Income per Employee (TTM) -75,124
Receivable Turnover Ratio (TTM) 20.06
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.61

Profitability Ratios Current
Gross Margin (MRQ) 44.25 %
Operating Margin (MRQ) -116.42 %
Net Margin (MRQ) -115.42 %
Net Cash Flow Margin (MRQ) 12 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Accolade Inc's Segments
Access fees    67.92 % of total Revenue
Usage-based fees    32.08 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.